{
    "nctId": "NCT05612100",
    "briefTitle": "Endocrine Therapy-Induced Alopecia in Postmenopausal and Premenopausal Female Breast Cancer Patients",
    "officialTitle": "Endocrine Therapy-Induced Alopecia Natural History Evaluation Among Female Breast Cancer Survivors",
    "overallStatus": "RECRUITING",
    "conditions": "Breast Carcinoma",
    "studyType": "OBSERVATIONAL",
    "phase": "N/A",
    "allocation": "N/A",
    "primaryPurpose": "N/A",
    "enrollmentCount": 170,
    "primaryOutcomeMeasure": "Estimation and characterization of patient-reported treatment-emergent alopecia within and across the cohorts",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Age \\>= 18 years\n* Women with a diagnosis of breast cancer who are being treated with curative intent, with the one exception being women who are receiving CDK4/6 inhibitors (these patients being allowed to have more advanced disease)\n* Provide informed consent\n* Ability to complete questionnaire(s) by themselves or with assistance\n* Filling into one of the 5 groups (understanding that groups will close once they complete their accrual goals of 30 patients)\n* Willingness to complete questionnaires every 3 months\n* Ability to complete the first questionnaire within 2 weeks of therapy initiation (for the four arms that are receiving adjuvant hormonal therapy)\n\n  * For patients starting tamoxifen or an aromatase inhibitor: within 2 weeks of starting tamoxifen or aromatase inhibitor\n  * For patients starting a CDK 4/6 inhibitor: within 2 weeks of starting the CDK 4/6 inhibitor (patients may have started an aromatase inhibitor at any time prior to initiation of CDK 4/6 inhibitor).\n\nExclusion Criteria:\n\n* Verbal baseline alopecia \\>= 2 on an 11 point scale (from none = 0 to severe = 10). The question to use for this item is: Please rate your hair thinning or loss on a scale from 0 to 10, with 0 being no hair loss and 10 being complete hair loss\n* Planned receipt of chemotherapy or another cancer-directed therapy concurrently (e.g., everolimus, etc.; note that a CDK4/6 inhibitor is allowed within cohort 3)\n* Prior use of endocrine therapy for breast cancer\n* Receipt of chemotherapy over the previous 6 months",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}